Monitoring C-Reactive Protein in Biologic Naive Patients With Ulcerative Colitis Undergoing Infliximab Remission Induction Therapy

被引：0
|
作者：
Suzuki, Yasuo
Iwasa, Ryota
Yamada, Akihiro
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1122
引用
收藏
页码：S381 / S381
页数：1
相关论文
共 50 条
  • [1] Vedolizumab is superior to infliximab in biologic naive patients with ulcerative colitis
    Sablich, Renato
    Urbano, Maria Teresa
    Scarpa, Marco
    Scognamiglio, Federico
    Paviotti, Alberto
    Savarino, Edoardo
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [2] Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein, GR
    INFLAMMATORY BOWEL DISEASES, 2001, 7 (02) : 89 - 93
  • [3] Effectiveness of infliximab as remission-induction therapy in patients with active ulcerative colitis
    Yokoyama, K.
    Kawagishi, K.
    Ooka, S.
    Mukae, M.
    Sada, M.
    Kobayashi, K.
    Koizumi, W.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S277 - S277
  • [4] C-reactive protein improvement after vedolizumab induction phase is associated with remission after 6 months of treatment in ulcerative colitis patients
    Zezos, P.
    Kabakchiev, B.
    Weizman, A. V.
    Nguyen, G. C.
    Narula, N.
    Croitoru, K.
    Steinhart, A. H.
    Silverberg, M. S.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S190 - S190
  • [5] Comparative Effectiveness and Safety of Infliximab and Adalimumab for Ulcerative Colitis in Biologic-Naive Patients
    Singh, Siddharth
    Sangaralingham, Lindsey R.
    Heien, Herbert
    Anderson, Stephanie S.
    Shah, Nilay
    Loftus, Edward V.
    GASTROENTEROLOGY, 2015, 148 (04) : S175 - S176
  • [6] Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study
    Emily C. L. Wong
    Shahin Merat
    Cristina Monaco
    Parambir S. Dulai
    Vipul Jairath
    John K. Marshall
    Walter Reinisch
    Neeraj Narula
    Digestive Diseases and Sciences, 2023, 68 : 2635 - 2646
  • [7] C-reactive protein/albumin ratio: a novel biomarker for monitoring of the disease activity in Ulcerative Colitis patients
    Tomasic, V.
    Biscanin, A.
    Cacic, P.
    Palac, L.
    Dorosulic, Z.
    Kralj, D.
    Babic, F.
    Ogresta, D.
    Hrabar, D.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I330 - I332
  • [8] Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched Study
    Wong, Emily C. L.
    Merat, Shahin
    Monaco, Cristina
    Dulai, Parambir S.
    Jairath, Vipul
    Marshall, John K.
    Reinisch, Walter
    Narula, Neeraj
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (06) : 2635 - 2646
  • [9] Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
    Yamamoto, Takayuki
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 58 (05) : 546 - 547
  • [10] C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study
    Ryota Iwasa
    Akihiro Yamada
    Koji Sono
    Ryuichi Furukawa
    Ken Takeuchi
    Yasuo Suzuki
    BMC Gastroenterology, 15
12345